MedTrace Logo

PCA Administration in Prosthetic Joint Infection

NCT06591741 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-08-20

No results posted yet for this study

Summary

Determine if dietary protocatechuic acid (PCA) will affect health biomarkers in patient undergoing revision surgery for a knee prosthetic joint infection

Conditions

  • Prosthetic Joint Infection

Interventions

DIETARY_SUPPLEMENT

Oral PCA

PCA 1,000 mg BID until surgery, held until anticoagulation, and resumed at 1,000 mg daily for 4 years

Sponsors & Collaborators

  • Lanny Johnson, M.D.

    collaborator UNKNOWN

  • Leo Whiteside, M.D.

    collaborator UNKNOWN

  • Dr. Dean Reeves Clinic

    lead OTHER

Principal Investigators

  • Kenneth D Reeves, M.D. · K. Dean Reeves, M.D., P.A.

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2028-07-31
Completion
2028-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06591741 on ClinicalTrials.gov